The Alzheimer's Target Everyone Missed
Dan's team is going after what they believe are "the real toxic drivers"
Dan O'Connell, CEO of Acumen Pharmaceuticals, recently shared his team's hypothesis that could reshape Alzheimer's treatment.
The theory: While most drugs target amyloid plaques, Dan believes 'we've identified the toxic target within the amyloid field' ...amyloid oligomers. As he explained, these smaller aggregates "have a propensity to bind to neurons directly" and may be more potent toxins than plaques.
See the full podcast video here.
Supporting evidence: Dan noted that human data showed these oligomers were "70-fold elevated in Alzheimer's patients."
The Trial Design That Tackles Recruitment
Dan described their Phase 2 approach to solving real enrollment challenges:
- Blood-based screening reduced negative PET scans by 50%+
- 540 patients enrolled - participants have two-thirds chance of getting active drug
- Open-label extension for everyone after blinded period
- FDA Fast Track designation secured
Early Phase 1 Signals
Dan shared their Phase 1 results:
- 6 cases of brain swelling (ARIA) in 48 patients - "five of those were asymptomatic and one was very mildly symptomatic"
- "20 to 25% reduction" in amyloid PET signal after 3 doses
- Demonstrated target engagement with dose response
Dan noted they were "pushing doses that with other agents had produced really dramatic symptomatic ARIA," suggesting a potentially improved safety margin.
What's Next
Phase 2 readout expected before end of 2025. Dan mentioned potential accelerated approval discussions if data supports it.
Looking ahead, Dan sees the field moving toward "combination approaches that are likely to produce the most robust outcome for patients."
Bottom Line
After evaluating "roughly 5,000 opportunities" over 25 years, Dan went all-in on Acumen. His prediction? The field will move toward "combination approaches that are likely to produce the most robust outcome for patients."e."
Comments ()